Systemic Sclerosis Market Size, Share, Industry, Forecast and outlook (2023-2030)

Global Systemic Sclerosis Market is segmented By Type (Limited, Diffuse), By Drug Type (Corticosteroids, Immunosuppressive Agents, Endothelin Receptor Agonists, Calcium Channel Blockers, Phosphodiesterase 5 Inhibitors, Chelating Agents, Prostacyclin Analogues, H2 Blockers, Proton Pump Inhibitors, ACE Inhibitors), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Systemic Sclerosis Market Overview

The Global Systemic Sclerosis Market is expected to grow at a CAGR of 6.0% during the forecasting period (2023-2030). Systemic sclerosis (SSc) is a systemic connective tissue disease of unknown etiology that affects the skin, blood vessels, muscles, joints, and a variety of internal organs, such as the digestive tract, heart, lungs, and kidneys.

• The global Systemic sclerosis treatment market is estimated to reach USD 1.4 million by 2024.

Systemic Sclerosis Market Growth

• Primary market drivers include increased use of expensive biologics, the rise in clinical trials for systemic sclerosis, high acceptance of new therapies by patients, and new drug approvals.

• However, delay in diagnosis and lack of safe and effective treatments will restrain the market growth.

Systemic Sclerosis Market Segmentation Analysis

• The Global Systemic sclerosis market report segments the market by type, drug type, and region.

• Based on the extent of skin involvement, the market is segmented into Limited cutaneous systemic sclerosis (lcSSc), or limited scleroderma, and Diffuse cutaneous systemic sclerosis (dcSSc), or diffuse scleroderma.

• Limited cutaneous systemic sclerosis is the more common type of SSc.

• Based on drug type, the market is segmented into Corticosteroids, Immunosuppressive Agents, Endothelin Receptor Agonists, Calcium Channel Blockers, PDE-5 Inhibitors, Chelating Agents, Prostacyclin Analogues, H2 Blockers, Proton Pump Inhibitors, and ACE Inhibitors.

• Regarding the drug category, the segment of immunosuppressive agents is expected to retain dominance over the forecast period.

• Regionally, the market is segmented into five major regions, namely North America, South America, Europe, Asia Pacific, and RoW.

• North America will dominate the market. The US has an annual incidence of about 20 cases per 1 million adults.

Scope of the Report

• The report profiles the following companies of Systemic sclerosis market – Actelion, Roche/Genentech, BMS, Allergan, GSK, Biogen, Novartis, Teva, MedImmune, Celgene, Chugai, ASTA, Aspen, Pfizer, Eli Lilly, Bayer, and many more.

By Type

• Limited

• Diffuse

By Drug Type

• Corticosteroids

• Immunosuppressive Agents

• Endothelin Receptor Agonists

• Calcium Channel Blockers

• Phosphodiesterase 5 Inhibitors

• Chelating Agents

• Prostacyclin Analogues

• H2 Blockers

• Proton Pump Inhibitors

• ACE Inhibitors

By Region

• Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)

• Europe (Germany, France, The UK, Italy, Spain, Rest of Europe)

• North America (The USA, Canada, Mexico)

• South America (Brazil, Argentina, Rest of South America)

• Rest of the World